Blocking DLL4 signalling using anti-DLL4 antibody effectively delayed tumour growth possibly by disrupting functional angiogenesis [6–8, 19, 20, 47], implying that DLL4 is a dominant ligand over JAG1 in tumour angiogenesis and tumour growth. The gene discussed is DLL4; the disease is neoplasm.